Page last updated: 2024-12-07

leucylleucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leucylleucine, also known as di-leucine, is a dipeptide composed of two leucine amino acid residues. It is a naturally occurring compound that is found in various proteins and peptides. Its synthesis can be achieved through various methods, including enzymatic reactions and chemical synthesis. Research into leucylleucine has revealed several interesting effects. For instance, studies have shown that it may have potential as an anti-inflammatory agent, exhibiting anti-inflammatory properties. Furthermore, it has been implicated in regulating certain metabolic processes, such as glucose metabolism. The study of leucylleucine is of interest due to its potential role in health and disease. Its anti-inflammatory properties and its involvement in metabolic regulation make it a promising target for further investigation. Understanding the mechanisms behind its actions could lead to the development of new therapeutic strategies for various conditions.'

Leu-Leu : A dipeptide formed from two L-leucine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

leucylleucine: RN given refers to (DL-Leu-DL-Leu)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID76807
CHEMBL ID54933
CHEBI ID73531
SCHEMBL ID235250
MeSH IDM0115552
PubMed CID94244
CHEMBL ID1221715
CHEBI ID6418
SCHEMBL ID235249
MeSH IDM0115552

Synonyms (65)

Synonym
3303-31-9
nsc 89185
einecs 221-976-6
n-l-leucyl-l-leucine
leu-leu
l-leucyl-l-leucine ,
(s)-2-((s)-2-amino-4-methyl-pentanoylamino)-4-methyl-pentanoic acid
2-(2-amino-4-methyl-pentanoylamino)-4-methyl-pentanoic acid
bdbm50188496
CHEMBL54933 ,
chebi:73531 ,
(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoic acid
AKOS010420853
ll dipeptide
l-leu-l-leu
h-leu-leu-oh
h-l-leu-l-leu-oh
(s)-2-((s)-2-amino-4-methylpentanamido)-4-methylpentanoic acid
leucine, leucyl-
SCHEMBL235250
leu-leu-oh
DTXSID00186696
mfcd00065185
leucine leucine dipeptide
leucine-leucine dipeptide
l-l dipeptide
Q27140613
DS-14566
(2s)-2-[[(2s)-2-azaniumyl-4-methylpentanoyl]amino]-4-methylpentanoate
CS-W009358
HY-W008642
nsc89185
nsc-89185
CHEMBL1221715
chebi:6418 ,
nsc-524455
nsc524455
leucyl-leucine
2883-36-5
MAYBRIDGE1_006550
leucylleucine
HMS560B16
2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoic acid
AKOS009159083
2-(2-amino-4-methylpentanamido)-4-methylpentanoic acid
einecs 220-741-5
n-dl-leucyl-dl-leucine
FT-0637578
FT-0634764
SCHEMBL235249
dl-leucine, n-dl-leucyl-
LCPYQJIKPJDLLB-UHFFFAOYSA-N
n-(2-amino-4-methylpentanoyl)leucine #
leucylleucin
n-(2-amino-4-methylpentanoyl)leucine
FT-0771183
3-amino-2-heptanone
3272-06-8
FT-0772404
DTXSID30938827
n-(2-amino-1-hydroxy-4-methylpentylidene)leucine
Q27107201
2-((2-amino-4-methylpentanoyl)amino)-4-methylpentanoic acid
STARBLD0014418
SY074953

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" albicans to some toxic peptides in the presence of L-lysine may be attributed to an increased rate of transport of these peptides."( Toxicity of oxalysine and oxalysine-containing peptides against Candida albicans: regulation of peptide transport by amino acids.
Basrai, MA; Becker, JM; Miller, D; Naider, F; Zhang, HL, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
L-aminoacyl-L-amino acid zwitterionA dipeptide zwitterion that is the zwitterionic form of an L-aminoacyl-L-amino acid having a negatively charged carboxyl terminus and a positively charged amino terminus.
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)170.00000.18000.19000.2000AID266249
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)170.00000.00020.660310.0000AID266249
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID680825TP_TRANSPORTER: inhibition of VACV uptake (VACV: 20 uM, Leu-Leu: 10000 uM) in PEPT1-expressing CHO cells1999The Journal of pharmacology and experimental therapeutics, Apr, Volume: 289, Issue:1
Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266248Ratio of %GSmax to EC50 for human PEPT1 activation2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID228722Bitter tasting threshold was expressed as log 1/T.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID500815Activation of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (12.50)18.7374
1990's8 (14.29)18.2507
2000's19 (33.93)29.6817
2010's17 (30.36)24.3611
2020's5 (8.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]